Tirzepatide Once Weekly for the Treatment of Obesity

20222,866 citationsJournal Articlebronze Open Access

Authors

Ania M. Jastreboff · Yale University

Louis J. Aronne · Cornell University

Nadia N. Ahmad · Eli Lilly (United States)

Sean Wharton · McMaster University

Lisa Connery

Breno Edson Sendão Alves

Arihiro Kiyosue

Shuyu Zhang · Eli Lilly (United States)

Abstract

In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).

Topics & Keywords

Pharmacology and Obesity Treatment Diabetes Treatment and Management Diet and metabolism studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 387, Issue 3, pp. 205-216

DOI: 10.1056/nejmoa2206038

Field-Weighted Citation Impact: 446.29